GLOBAL BLOOD THERAPEUTICS IN (GBT)

Company Profile

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. The company is headquartered in South San Francisco, California and currently employs 457 full-time employees. The company went IPO on 2015-08-12. The firm is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). The company is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address pain crises associated with the disease, and GBT021601 (GBT601), the Company’s next-generation HbS polymerization inhibitor. The firm is focused on areas of the United States, Europe, the Gulf Cooperation Council (GCC), region of the Middle East, and Latin America.

Company Info

GLOBAL BLOOD THERAPEUTICS IN

181 Oyster Point Blvd

South San Francisco CALIFORNIA 94080

P: 16507417700.0

CEO: Ted W. Love

Employees: 457

Website: https://www.gbt.com/